Read more about the research by NRG Therapeutics.
More than £2m awarded to research on mitochondria and Parkinson’s disease
Author: Scarlett SherriffPublished: 9 June 2022
Prep: Cook: Serves:
Researchers at UK biotech startup NRG Therapeutics are developing potential treatments that may help slow the progression of Parkinson’s by protecting the mitochondria – a part of every human cell that works to power chemical reactions.
The company has now received a £2.68m award from government-backed agency Innovate UK to continue its research.
Their research built upon previous findings that damage to mitochondria in the substantia nigra – an area of the brain associated with dopamine – may be linked to Parkinson’s. The scientists developed molecules that keep a ‘pore’ in the mitochondria closed, which stops calcium flowing into it, preventing a process that eventually ruptures the powerhouse of the cell and leads to its death.
The new funding award follows previous investment from Parkinson’s UK and the Michael J Fox Foundation.
For more information on the latest Parkinson’s research, please visit the EPDA website.
Share this story
Researchers investigate link between Parkinson’s disease and Covid-19
Researchers in the US have explored the link between Covid-19 and the riskREAD MORE
Study explores links between brain volume and Parkinson’s disease
Researchers from Germany have investigated how volume decreases in certainREAD MORE
Study suggests why neurons die in Parkinson’s disease
Researchers at the University of Córdoba, Spain, have discovered how a cerREAD MORE